This is the Peptevity compound catalog — one evidence-graded monograph per peptide. Each page separates animal/in-vitro evidence from human evidence, grades every claim A–F, and states the compound’s dated FDA and legal status. We sell nothing and link to no vendor. For the live regulatory picture, see the 2026 regulatory tracker; for how the grades work, see our evidence-grading methodology.
The catalog
| Compound | What it is | Evidence at a glance | Status |
|---|---|---|---|
| BPC-157 | Synthetic gastric pentadecapeptide | Healing claims animal-only (Grade C); no human RCTs | Not FDA-approved; July 2026 PCAC review |
| “Wolverine peptide” | Marketing nickname for BPC-157 | Hype framing; real evidence is BPC-157’s | Not FDA-approved |
| TB-500 | Synthetic thymosin β-4 fragment | Animal-dominant; minimal human data | Not FDA-approved; July 2026 PCAC review |
| BPC-157 vs TB-500 | The “wolverine stack” comparison | Both animal-dominant; neither human-proven | Both not FDA-approved |
| GHK-Cu | Copper tripeptide-1 | Topical skin = Grade B human; systemic = animal/in-vitro | Cosmetic ingredient; injectable RUO |
| Retatrutide | GIP/GLP-1/glucagon triple agonist | Strong Phase 3 human data (TRIUMPH-1) | Investigational — not approved |
| Retatrutide side effects | What trials document | Predominantly GI, dose-dependent (human trial data) | Investigational — not approved |
How to read a monograph
Every compound page leads with a self-contained answer, carries a dated Regulatory status box, grades each claim by species and study type, and cites every efficacy or safety statement to a primary source. Where the marketing runs ahead of the evidence, we say so. See are peptides safe? for the cross-catalog safety view and animal vs human evidence for why preclinical results don’t transfer by default.
Every claim above is cited inline to a primary source. See how we grade evidence and our sourcing & citation policy.